Following a complete response letter last year, Satsuma Pharmaceuticals Inc. received U.S. FDA approval of dihydroergotamine nasal powder to treat acute migraine with or without aura. Branded Atzumi, ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...